May 23, 2025 — NeoMatrix Therapeutics (NMT) is proud to announce that NMT President and Chief Scientific Officer Dr. Richard Clark has...

Neomatrix Therapeutics, Inc. is pleased to announce that Joachim Kohn, PhD has joined the company as its Chief Scientific Advisor.  ...

Experienced Business Advisor who has led several therapeutics to market joins NeoMatrix Therapeutics, Inc.   April 18, 2025 — NeoMatrix...

Novel Peptide Progresses to Phase 2 for the Treatment of Severe Burns STONY BROOK, NY, February 5, 2025 (EINPresswire.com) – NeoMatrix...

NeoMatrix Therapeutics (NMT) Peptide Discovery Advances Treatment of Burn Injury. Novel Peptide Shows Promise for the Treatment of Severe...

- Novel Peptide to Advance to Phase 2 for the Treatment of Severe Burns -

- Potential First-in-Class Treatment for Serious Burn Injuries Targets PDGF -